Welcure Drugs

Why is Welcure Drugs & Pharmaceuticals Ltd falling/rising?

As of 14-Aug, the stock price of Welcure Drugs & Pharmaceuticals Ltd is currently at 0.24, reflecting a 4.35% increase today. However, despite this short-term rise, the stock has significant long-term declines and is trading below all moving averages, indicating a weak overall sentiment.

As of 14-Aug, the stock price of Welcure Drugs & Pharmaceuticals Ltd is rising, currently at 0.24, with a change of 0.01, representing an increase of 4.35%. This rise is notable as the stock has outperformed its sector by 5.21% today. However, it is important to consider the broader context of the stock's performance. Over the past week, the stock has declined by 4.00%, and it has experienced significant losses over longer periods, including a year-to-date decline of 42.86% and a one-year drop of 77.14%. <BR><BR>Despite today's positive movement, the stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), indicating a longer-term downward trend. Additionally, there has been a decrease in investor participation, with delivery volume falling by 16.67% compared to the 5-day average. This suggests that while there is a temporary rise in price, the overall sentiment towards the stock remains cautious, and the long-term outlook appears weak.

Which are the latest news on Welcure Drugs?

Who are in the management team of Welcure Drugs?

The management team of Welcure Drugs includes D C Jain (Non-Executive & Non-Independent Director), Sudhir Chandra (Managing Director), Mitashi Bisaria (Director & Company Secretary), Gagan Juneja (Non-Executive & Independent Director), Mohd. Shahbaz Alam (Independent Director), Sitaben S Patel (Additional Director), and Rajeev Mehra (Additional Director).

The management team of Welcure Drugs includes the following members:<BR><BR>1. **D C Jain** - Non-Executive & Non-Independent Director<BR>2. **Sudhir Chandra** - Managing Director<BR>3. **Mitashi Bisaria** - Director & Company Secretary<BR>4. **Gagan Juneja** - Non-Executive & Independent Director<BR>5. **Mohd. Shahbaz Alam** - Independent Director<BR>6. **Sitaben S Patel** - Additional Director<BR>7. **Rajeev Mehra** - Additional Director<BR><BR>If you need more specific information about their roles or contributions, feel free to ask!

What does Welcure Drugs do?

Welcure Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1992, with a recent net profit of -50 Cr as of March 2026 and a market cap of INR 30 Cr. Key metrics include a P/E of 1.00 and a return on equity of 36.50%.

Overview:<BR>Welcure Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Incorporated on 4th June, 1992, Welcure Drugs And Pharmaceuticals Limited was promoted by D C Jain, Sanjeev Jain, and Sandeep Jain. The company has reported a net profit of -50 Cr for the quarterly results ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -50 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 30 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 1.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.01<BR>Return on Equity: 36.50%<BR>Price-to-Book: 0.31<BR><BR>Contact Details:<BR>Address: B-9 & 10 Laxmi Towers, L S C Block-C Saraswati Vihar Delhi New Delhi : 110034<BR>Phone: 91-011-2701 1428<BR>Email: investor.welcure@gmail.com<BR>Website: https://welcuredrugs.com

Who are the peers of the Welcure Drugs?

Welcure Drugs' peers include Lasa Supergeneri, Roopa Industries, Centuple Global, Medi Caps, Guj. Terce Labs., Venmax Drugs, Cian Healthcare, Ishita Drugs, and Bacil Pharma. Cian Healthcare leads in 1-year returns at 193.85%, while Welcure Drugs has the lowest at -77.67%.

Peers: The peers of Welcure Drugs are Lasa Supergeneri, Roopa Industries, Centuple Global, Medi Caps, Guj. Terce Labs., Venmax Drugs, Cian Healthcare, Ishita Drugs, and Bacil Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Centuple Global, while Average management risk is found at Welcure Drugs and the rest. Below Average management risk is noted for Lasa Supergeneri, Roopa Industries, Medi Caps, Guj. Terce Labs., Venmax Drugs, Cian Healthcare, Ishita Drugs, and Bacil Pharma. Growth is Excellent at Roopa Industries, Good at Centuple Global, and Below Average at Welcure Drugs, Lasa Supergeneri, Medi Caps, Guj. Terce Labs., Venmax Drugs, Cian Healthcare, Ishita Drugs, and Bacil Pharma. Average capital structure is seen at Lasa Supergeneri, Medi Caps, and the rest have Below Average, except for Welcure Drugs and Centuple Global, which have Good capital structure.<BR><BR>Return Snapshot: Cian Healthcare has the highest 1-year return at 193.85%, while Welcure Drugs has the lowest at -77.67%. This indicates that Welcure Drugs' 1-year return is significantly lower than that of Cian Healthcare. Additionally, several peers, including Lasa Supergeneri, Medi Caps, Guj. Terce Labs., Venmax Drugs, Ishita Drugs, and Bacil Pharma, have negative six-month returns.

How big is Welcure Drugs?

Summary could not be generated.

As of 14th August, <BR><BR>Market Cap: Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 29.66 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 365.53 Cr, while the sum of Net Profit for the same period shows a loss of 16.99 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period, but data for Shareholder's Funds and Total Assets is unavailable.

Should I buy, sell or hold Welcure Drugs & Pharmaceuticals Ltd?

Are Welcure Drugs & Pharmaceuticals Ltd latest results good or bad?

Welcure Drugs & Pharmaceuticals Ltd's latest results are concerning, showing a 100% decline in net sales to ₹0.00 and an operating margin drop to 0.0%. The reported net profit of ₹1.07 crores was misleading, driven entirely by non-operating income, indicating serious operational distress and risks to future viability.

The latest results for Welcure Drugs & Pharmaceuticals Ltd are concerning and indicate significant operational distress. In Q3 FY26, the company reported net sales of ₹0.00, marking a dramatic 100% decline from the previous quarter. This is alarming as it suggests a complete cessation of commercial operations. <BR><BR>While the company reported a net profit of ₹1.07 crores, this figure is misleading as it was primarily driven by other income of ₹1.46 crores, which accounted for over 100% of the profit before tax. The core pharmaceutical business did not contribute to profitability, indicating serious issues with its operational viability.<BR><BR>The operating margin has also dropped to 0.0%, down from 17.31% in the previous quarter, highlighting a severe decline in operational performance. The return on equity (ROE) of 33.54% appears high but is not reflective of sustainable business operations, given the lack of revenue generation.<BR><BR>Overall, the results suggest a troubling situation for Welcure Drugs, with significant risks regarding its future viability and operational continuity. Investors should approach this stock with caution, as the combination of zero revenue and reliance on non-operating income raises serious red flags about the company's financial health.

How has been the historical performance of Welcure Drugs?

Welcure Drugs experienced a significant turnaround in the fiscal year ending March 2025, reporting net sales of 24.55 crore and a profit after tax of 2.17 crore, compared to losses in the previous year. This marked its first year of substantial revenue generation and profitability, with improved operating and profit margins.

Answer:<BR>The historical performance of Welcure Drugs shows significant changes, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Welcure Drugs reported net sales of 24.55 crore, a notable increase from previous years where sales were non-existent. The total operating income also rose to 24.55 crore, reflecting the same trend. The company's total expenditure, excluding depreciation, was recorded at 23.67 crore, which is a substantial increase from 0.23 crore in March 2024. Operating profit (PBDIT) for March 2025 was 2.79 crore, a recovery from a loss of 0.14 crore in the previous year. Profit before tax reached 2.78 crore, compared to a loss of 0.17 crore in March 2024, leading to a profit after tax of 2.17 crore, up from a loss of 0.17 crore. The earnings per share (EPS) improved to 0.02 from a negative 0.13 in the prior year, indicating a positive shift in profitability. The operating profit margin for March 2025 was 3.58%, and the profit after tax margin stood at 8.84%, both reflecting a strong performance compared to the previous years where these metrics were at zero. Overall, the financial results for March 2025 demonstrate a significant turnaround for Welcure Drugs, marking its first year of substantial revenue generation and profitability.

What is the bonus history of Welcure Drugs?

Welcure Drugs has announced a 1:10 bonus issue, with an ex-date and record date set for October 16, 2025. Shareholders will receive 1 additional share for every 10 shares held.

Welcure Drugs has a recent bonus issue history where they announced a 1:10 bonus issue. The ex-date for this bonus is set for October 16, 2025. This means that for every 10 shares held, shareholders will receive 1 additional share as a bonus. The record date for this bonus is also October 16, 2025. If you have any more questions about Welcure Drugs or need further details, feel free to ask!

Is Welcure Drugs overvalued or undervalued?

As of September 15, 2025, Welcure Drugs is considered an attractive investment due to its low PE ratio of 3.41 and significant undervaluation compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -28.11%.

As of 15 September 2025, the valuation grade for Welcure Drugs has moved from very attractive to attractive. The company is currently considered undervalued, given its low PE ratio of 3.41, a price-to-book value of 0.92, and an EV to EBITDA of 6.45. These ratios indicate that the stock is trading at a significant discount compared to its earnings and book value.<BR><BR>In comparison to its peers, Welcure Drugs stands out with a much lower PE ratio than Sun Pharma (33.52) and Divi's Lab (69.55), both of which are classified as expensive. Additionally, its PEG ratio of 0.01 further emphasizes its undervaluation relative to the industry. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -28.11% compared to the Sensex's 4.67%, the fundamental metrics suggest that Welcure Drugs presents a compelling investment opportunity at its current price.

When is the next results date for Welcure Drugs?

Welcure Drugs will announce its results on 05 August 2025.

Welcure Drugs will declare its results on 05 August 2025.

Who are the top shareholders of the Welcure Drugs?

The top shareholders of Welcure Drugs are primarily individual investors, holding 98.99% of the shares, with Rahul Ratansingh Sikarwar being the largest individual shareholder at 9.78%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Welcure Drugs primarily consist of individual investors, who hold a significant 98.99% of the company's shares. Among public shareholders, the highest individual shareholder is Rahul Ratansingh Sikarwar, with a holding of 9.78%. There are no institutional investors or mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Welcure Drugs?

As of May 8, 2025, Welcure Drugs shows a bullish technical trend supported by strong MACD, Bollinger Bands, and moving averages, though caution is advised due to a mildly bullish weekly Dow Theory trend.

As of 8 May 2025, the technical trend for Welcure Drugs has changed from mildly bullish to bullish. The weekly and monthly MACD are both bullish, indicating strong momentum. Bollinger Bands also reflect a bullish stance on both time frames. Daily moving averages are bullish, supporting the upward trend. The KST is bullish on both weekly and monthly charts, further confirming the positive outlook. However, the Dow Theory shows a mildly bullish trend on the weekly but no trend on the monthly, suggesting some caution. Overall, the current technical stance is bullish with strong indicators supporting this view.

Has Welcure Drugs declared dividend?

No Dividend History Available